Healthcare can be complicated.
Your cardiology news shouldn’t be.
Join thousands of cardiology leaders today.
Atrial Fibrillation October 17, 2024
InCarda Gets Mixed Results in AFib Inhaler Trial October 17, 2024
AFib inhalers took a small step closer to becoming a reality after InCarda Therapeutics’ Phase 3 RESTORE-1 trial showed that its FlecIH-103 inhaled flecainide formulation can rapidly convert paroxysmal AFib to normal sinus rhythm. However, challenges with the study suggest that InCarda has more work to do in order to achieve this reality. The new […]
Cholesterol Reduction October 10, 2024
AstraZeneca Adds Lp(a) Candidate with CSPC Licensing Move October 10, 2024
AstraZeneca expanded its cardiovascular pipeline this week, signing an exclusive license agreement for CSPC Pharmaceutical Group’s Lp(a) disruptor candidate, YS2302018. The deal comes with a $100M upfront investment that could reach $1.92B depending on further milestones. CSPC’s YS2302018 addresses a sizable target market, noting that nearly 70% of patients with CVD aren’t meeting guideline-directed LDL-C […]
Heart Failure October 7, 2024
Finerenone’s Early Heart Failure Impact October 7, 2024
The FINEARTS-HF trial already showed that Bayer’s nsMRA finerenone (Kerendia) has the potential to slash mortality and event rates in HFpEF and HFmrEF patients, and new analysis suggests that its impact could be even greater if used earlier. The original FINEARTS-HF trial presented at ESC 2024 saw finerenone drive a 16% reduction in cardiovascular death […]
Heart Failure October 3, 2024
EMBARK-HFpEF Trial Flexes Mavacamten’s HF Potential October 3, 2024
A new HFpEF treatment might be on the horizon, after results from the EMBARK-HFpEF trial showed that BMS’ hypertrophic cardiomyopathy treatment, mavacamten (Camzyos), safely improved key HFpEF symptoms and biomarkers. To test mavacamten’s HFpEF potential, the open-label Phase 2a EMBARK-HFpEF trial treated 30 HFpEF patients with mavacamten (avg age 76, NYHA Class II & III, […]